Olympus will pay as much as 11 billion yen ($92 million) to settle two lawsuits based in a 2011 accounting scandal. This comes just as the camera and medical imaging company has been identified as one of several companies whose dirty duodenoscopes have infected some patients with antibiotic-resistant bacteria.
Japan's pharmaceutical market is forecast to reach close to the $80 billion mark by 2020, but three big "ifs" could keep it from reaching that mark, up from $72.8 billion in 2013.
For several years, Gilead Sciences CEO John Martin has collected annual compensation worth about $15 million and his stock gains since 2009 run into the hundreds of millions. But for a record-smashing year that vaulted his company into the ranks of the global top 10, Martin snared a comparatively small payoff in 2015.
The device industry is the source of wealth for 10 of the people on Forbes' annual list of the 400 richest people in America.
Michigan-based Neogen said Thursday that its third-quarter revenues grew 10% year over year to $68.4 million and net income rose 13% to $7.5 million, despite negative currency trends that continue to impede the company's overseas expansion plans.
Japan's Fujifilm Holdings will pay $307 million to buy all outstanding shares of NASDAQ-listed Cellular Dynamics International in a deal with will further expand its reach into regenerative medicine research.
Germany's Merck KGaA now considers the world's emerging markets as a group, with China a major driver, to be a greater revenue-producer than Europe, unit CEO Bernd Reckmann said in an interview.
The latest of nearly 5 months of speculation has Panasonic Healthcare counting on paying only $830 million for Bayer's diabetes device business it has been trying to sell off. Previous estimates had guessed a sale of up to $2.3 billion.
Japan's Otsuka Pharmaceuticals accused the U.S. FDA in a unique court suit of manipulating its regulatory procedures to kill off its 7-year exclusivity to market Abilify (aripiprazole) for treating Tourette syndrome in children.
India's Cadila Healthcare said it has bought out the shares of Bharat Serums and Vaccines to gain total control of their 10-year-old joint venture, Zydus BSV Pharma, and make it a wholly owned subsidiary.